SCHEMBL21483087

SCHEMBL21483087

OC[C@H]1CN(Cc2ccccc2)CCC1(F)F

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
LMNA P02545 1/20 0.48
MAPT P10636 1/20 0.48
MAPK1 P28482 1/20 0.48
OPRL1 P41146 1/20 0.48
TSHR P16473 2/20 0.47
POLB P06746 2/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
HIF1A Q16665 1/20 0.47
CYP3A4 P08684 1/20 0.46
HSD17B10 Q99714 1/20 0.46
SIGMAR1 Q99720 4/20 0.46
DRD4 P21917 1/20 0.46
CYP2D6 P10635 2/20 0.46
CHRM2 P08172 1/20 0.45
CHRM3 P20309 1/20 0.45
GBA1 P04062 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12490905 1.00 ALDH1A1 (0.48) ALDH1A1MEN1KMT2ALMNAMAPT
SCHEMBL21462564 1.00 ALDH1A1 (0.48) ALDH1A1MEN1KMT2ALMNAMAPT
SCHEMBL23464439 0.89 SIGMAR1 (0.49) ALDH1A1MEN1KMT2ALMNAMAPT
SCHEMBL20521716 0.85 GBA1 (0.47) ALDH1A1MEN1KMT2ATSHRSIGMAR1
SCHEMBL15398360 0.83 OPRD1 (0.48) ALDH1A1MAPK1TSHRCYP3A4CYP2D6
SCHEMBL21209747 0.82 OPRL1 (0.51) ALDH1A1MEN1KMT2ALMNAMAPT
SCHEMBL6331329 0.81 ALDH1A1 (0.49) ALDH1A1MEN1KMT2ALMNAMAPT
SCHEMBL29797081 0.81 ALDH1A1 (0.56) ALDH1A1MEN1KMT2ALMNAMAPT
SCHEMBL5871849 0.79 SIGMAR1 (0.46) ALDH1A1MEN1KMT2ALMNAMAPT
SCHEMBL22528005 0.79 ACHE (0.50) ALDH1A1MEN1KMT2ALMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4729127-A2 BCL6 INHIBITORS Cancer Research Technology Limited (GB) 2026-04-22 EP disclosed
US-20260042776-A1 BCL6 INHIBITORS CANCER RESEARCH TECH LTD (GB) 2026-02-12 US disclosed
US-12486285-B2 BCL6 inhibitors CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2025-12-02 US disclosed
CN-112334475-B BCL6 inhibitors 癌症研究技术有限公司 2024-10-29 CN disclosed
US-20230287003-A1 BCL6 INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-09-14 US disclosed
US-20230287003-A1 BCL6 INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-09-14 US disclosed
US-20230287003-A1 BCL6 INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-09-14 US disclosed
EP-4201939-A1 BCL6 INHIBITORS Cancer Research Technology Limited (GB) 2023-06-28 EP disclosed
EP-4201939-A1 BCL6 INHIBITORS Cancer Research Technology Limited (GB) 2023-06-28 EP disclosed
EP-3774817-B1 BCL6 INHIBITORS CANCER RESEARCH TECH LTD (GB) 2022-12-07 EP disclosed
EP-3774817-B1 BCL6 INHIBITORS CANCER RESEARCH TECH LTD (GB) 2022-12-07 EP disclosed
US-11512095-B2 BCL6 inhibitors THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2022-11-29 US disclosed
US-20210163497-A1 BCL6 INHIBITORS THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2021-06-03 US disclosed
US-20210163497-A1 BCL6 INHIBITORS THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2021-06-03 US disclosed
CN-112334475-A BCL6 inhibitor 癌症研究技术有限公司 2021-02-05 CN disclosed
WO-2019197842-A1 BCL6 INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2019-10-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210163497-A1 BCL6 INHIBITORS BCL6, BCL6B, BCL3 ALDH1A1 2602/4885MEN1 708/4885KMT2A 757/4885
US-20230287003-A1 BCL6 INHIBITORS BCL6, BCL6B, BCL3 ALDH1A1 2602/4885MEN1 708/4885KMT2A 757/4885
US-12486285-B2 BCL6 inhibitors BCL6, BCL6B, BCL3 ALDH1A1 2602/4885MEN1 708/4885KMT2A 757/4885
US-11512095-B2 BCL6 inhibitors BCL6, BCL6B, BCL3 ALDH1A1 2602/4885MEN1 708/4885KMT2A 757/4885
US-20260042776-A1 BCL6 INHIBITORS BCL6, BCL6B, BCL9 ALDH1A1 3510/4885MEN1 2126/4885KMT2A 423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.